ArticleDrug testing and analysis2026
Identification and Characterization of the Designer Opioid N-Pyrrolidino Fluetonitazene in Nasal Spray.
Article in Drug testing and analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Detection of drugs in non-biological samples serves as a fundamental basis for identifying emerging trends in the field of new psychoactive substances and provides valuable information for optimizing analytical methods within the field of chemical analysis. Nitazenes belong to this group of compounds and have been reported to cause poisonings. N-pyrrolidino fluetonitazene, also known as fluetonitazepyne (2-(4-(2-fluoroethoxy)benzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazole), is another emerging synthetic opioid that may contribute to the challenges faced globally. This article describes the identification and characterization of N-pyrrolidino fluetonitazene in a rarely reported medium for opioids: nasal spray. The sample investigated here was collected from a patient treated at the University Medicine Halle following first-time recreational use of a nasal spray and was submitted in an amber plastic bottle containing a small volume of a yellowish viscous liquid. The analytical techniques used for identifying this compound included gas chromatography-mass spectrometry, liquid chromatography-quadrupole time-of-flight mass spectrometry, nuclear magnetic resonance spectroscopy, and Fourier transform infrared spectroscopy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.